Business Description
Autolus Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US05280R1005
Share Class Description:
FRA:6A3A: ADRDescription
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.58 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.27 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.33 | |||||
| Beneish M-Score | -2.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 26 | |||||
| 3-Year EBITDA Growth Rate | 33.9 | |||||
| 3-Year EPS without NRI Growth Rate | 24.8 | |||||
| 3-Year FCF Growth Rate | 29.5 | |||||
| 3-Year Book Growth Rate | -45.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 19.42 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 326.73 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.16 | |||||
| 9-Day RSI | 34.84 | |||||
| 14-Day RSI | 37.79 | |||||
| 3-1 Month Momentum % | -3.26 | |||||
| 6-1 Month Momentum % | -4.3 | |||||
| 12-1 Month Momentum % | -11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.69 | |||||
| Quick Ratio | 13.69 | |||||
| Cash Ratio | 12.52 | |||||
| Days Sales Outstanding | 4.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -49.3 | |||||
| Shareholder Yield % | -73.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2162.28 | |||||
| Net Margin % | -2677.9 | |||||
| FCF Margin % | -2024.01 | |||||
| ROE % | -71.91 | |||||
| ROA % | -40.16 | |||||
| ROIC % | -175.39 | |||||
| 3-Year ROIIC % | -10598.97 | |||||
| ROC (Joel Greenblatt) % | -209.34 | |||||
| ROCE % | -31.79 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 62.39 | |||||
| PB Ratio | 1.57 | |||||
| Price-to-Tangible-Book | 1.57 | |||||
| EV-to-EBIT | -0.7 | |||||
| EV-to-EBITDA | -0.74 | |||||
| EV-to-Revenue | 13.99 | |||||
| EV-to-Forward-Revenue | 607.04 | |||||
| EV-to-FCF | -0.77 | |||||
| Price-to-GF-Value | 0.65 | |||||
| Price-to-Net-Current-Asset-Value | 2.03 | |||||
| Price-to-Net-Cash | 2.43 | |||||
| Earnings Yield (Greenblatt) % | -142.57 | |||||
| FCF Yield % | -27.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Autolus Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 9.284 | ||
| EPS (TTM) (€) | -1.117 | ||
| Beta | 1.21 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.31 | ||
| Volatility % | 85.81 | ||
| 14-Day RSI | 37.79 | ||
| 14-Day ATR (€) | 0.141218 | ||
| 20-Day SMA (€) | 2.912 | ||
| 12-1 Month Momentum % | -11 | ||
| 52-Week Range (€) | 2.62 - 7.1 | ||
| Shares Outstanding (Mil) | 266.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Autolus Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Autolus Therapeutics PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Autolus Therapeutics PLC Frequently Asked Questions
What is Autolus Therapeutics PLC(FRA:6A3A)'s stock price today?
The current price of FRA:6A3A is €2.70. The 52 week high of FRA:6A3A is €7.10 and 52 week low is €2.62.
When is next earnings date of Autolus Therapeutics PLC(FRA:6A3A)?
The next earnings date of Autolus Therapeutics PLC(FRA:6A3A) is 2025-03-14 Est..
Does Autolus Therapeutics PLC(FRA:6A3A) pay dividends? If so, how much?
Autolus Therapeutics PLC(FRA:6A3A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers